SEC Says Cannabis Pill Maker Ran $2M Securities Fraud

By Katryna Perera · September 28, 2021, 7:52 PM EDT

The U.S. Securities and Exchange Commission on Tuesday filed suit against the makers of the cannabis pill Idrasil, alleging that C3 International Inc. and its co-founders raised approximately $2 million from...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

U.S. Securities and Exchange Commission v. C3 International, Inc. et al

Case Number

Court

California Central

Nature of Suit

Securities/Commodities

Date Filed

September 28, 2021

Recent Articles By Katryna

November 04, 2024
Late New Evidence Can't Revive Investor Suit, Judge Says
October 31, 2024
Masimo Sues Ex-CEO Over 'Unprecedented' $450M Demand
October 28, 2024
SEC Sues To Enforce Subpoena On Telehealth Co.
September 27, 2024
Pharma Co. Amarin Beats Class Action Over Patent Issues
September 26, 2024
Healthcare REIT Defeats Investor Suit For Good
September 23, 2024
Mallinckrodt Brass Can't Avoid Investor Suit Over 2nd Ch. 11
September 23, 2024
SEC Scores $12M Judgment In Unregistered Dealer Case
September 05, 2024
Pharma Co. Verrica Fails To Shed Investor Suit Over FDA OK
August 21, 2024
Health Co. Investors Fight To Keep Suit Over Migrant Deal
August 06, 2024
Pharma Co. Founder Beats Suit Over Short-Swing Trading